Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR
E Kokalaki, B Ma, M Ferrari, T Grothier, W Hazelton… - Molecular Therapy, 2023 - cell.com
CAR T cells recognizing CD19 effectively treat relapsed and refractory B-ALL and DLBCL.
However, CD19 loss is a frequent cause of relapse. Simultaneously targeting a second …
However, CD19 loss is a frequent cause of relapse. Simultaneously targeting a second …
Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models
L Kua, CH Ng, JW Tan, HC Tan, CC Seh, F Wong… - Molecular Therapy, 2024 - cell.com
The chimeric antigen receptor (CAR) derived from the CD30 specific murine antibody, HRS-
3, has produced promising clinical efficacy with a favorable safety profile in the treatment of …
3, has produced promising clinical efficacy with a favorable safety profile in the treatment of …
Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate
Mesothelin (MSLN) has been a validated tumor-associated antigen target for several solid
tumors for over a decade, making it an attractive option for therapeutic interventions. Novel …
tumors for over a decade, making it an attractive option for therapeutic interventions. Novel …
Electrophilic proximity-inducing synthetic adapters enhance universal T cell function by covalently enforcing immune receptor signaling
NJ Serniuck, E Kapcan, D Moogk, AE Moore… - Molecular Therapy …, 2024 - cell.com
Proximity-induction of cell-cell interactions via small molecules represents an emerging field
in basic and translational sciences. Covalent anchoring of these small molecules represents …
in basic and translational sciences. Covalent anchoring of these small molecules represents …
Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22
S McComb, M Arbabi-Ghahroudi, KA Hay… - Molecular Therapy …, 2024 - cell.com
Chimeric antigen receptor (CAR) T cell therapies targeting B cell-restricted antigens CD19,
CD20, or CD22 can produce potent clinical responses for some B cell malignancies, but …
CD20, or CD22 can produce potent clinical responses for some B cell malignancies, but …
Ligand-induced segregation from large cell-surface phosphatases is a critical step in γδ TCR triggering
Gamma/delta (γδ) T cells are unconventional lymphocytes that recognize diverse ligands via
somatically recombined T cell antigen receptors (γδ TCRs). The molecular mechanism by …
somatically recombined T cell antigen receptors (γδ TCRs). The molecular mechanism by …
[PDF][PDF] Computationally dissecting autologous and therapy-induced immune responses at tissue and single cell level
G Moranzoni - 2023 - orbit.dtu.dk
This thesis presents research conducted from December 2020 to December 2023 within the
Single Cell Omics group at the Section for Bioinformatics, DTU Health Tech. The work was …
Single Cell Omics group at the Section for Bioinformatics, DTU Health Tech. The work was …
Refining chimeric antigen receptors via barcoded protein domain combination pooled screening
X Rios, O Pardias, MA Morales, P Bhattacharya… - Molecular Therapy, 2023 - cell.com
Chimeric antigen receptor (CAR)-T cells represent a promising frontier in cancer
immunotherapy. However, the current process for developing new CAR constructs is time …
immunotherapy. However, the current process for developing new CAR constructs is time …